$GH

Bell Michael Brian sold $257K of GH

Bell Michael Brian (Chief Financial Officer) sold 2,000 shares of Guardant Health, Inc. (GH) at $128.62 ($0.26M total) on 2026-06-05.

Original reporting
SEC EDGAR · Bell Michael Brian
Published Jun 8, 2026, 10:28 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 8, 2026, 10:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$GH
Neutral
medium confidence
Mentioned
$GH
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GHNeutralLow
01

Why it matters

The newest fact is the CFO’s open-market sale details (shares, price, and post-transaction holdings).

02

Market read

Traders may note insider selling as a mild sentiment datapoint, but there is no accompanying fundamental catalyst in the text.

03

What to watch

The article does not state whether the sale was for taxes, diversification, or other non-informational reasons; also no 10b5-1 plan is cited, which can cut both ways for interpretation.

Relevance 4/10Novelty 5/10Timing: Filed 2026-06-08 (covers sale dated 2026-06-05)

Background

This is an SEC Form 4 insider transaction disclosure for Guardant Health, Inc.

Company-level read

Ticker impact

$GHNeutralMedium confidence
Context

Guardant Health CFO Michael Brian Bell filed an open-market sale of 2,000 shares at $128.6203 on 2026-06-05 (Form 4).

Expected impact

Low near-term impact; any effect is likely sentiment-only and outweighed by upcoming company-specific catalysts.

Evidence & confidence

The filing is a disclosed open-market sale (no 10b5-1 plan stated) but is not accompanied by new operational/regulatory/financial information.

Market effects

Minimal; single insider sale does not materially change sector risk or read-across.

None indicated.

None indicated.

Counterpoint

Insider sales can be planned for liquidity/taxes and may not reflect bearish fundamentals, especially when not tied to a new negative event.

Key entities

  • Guardant Health, Inc.

    Subject of the Form 4 insider transaction; CFO sold shares in an open-market transaction.

  • Michael Brian Bell

    Chief Financial Officer who executed the reported sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$GHHigh

Guardant Health (GH) Wins a New Breast Cancer Role. Can Its Growth Justify the Price?

Guardant Health (GH) received FDA approval for its Guardant360 CDx test as a companion diagnostic for AstraZeneca's camizestrant in advanced breast cancer. The company reported Q2 2026 revenue growth of 44% to $335 million, with oncology revenue up 38% and screening revenue up significantly. Despite strong revenue growth, the company reported an adjusted EBITDA loss of $55.9 million and negative free cash flow.

$GHMed

Guardant360 CDx Receives European Approval as Companion Diagnostic for Camizestrant in ESR1-Mutated Advanced Breast Cancer

Guardant360 CDx received EU approval as a companion diagnostic for AstraZeneca's camizestrant in ER-positive, HER2-negative advanced breast cancer. The blood test detects ESR1 mutations, aiding treatment decisions. The approval follows similar nods in the US and Japan, based on the SERENA-6 trial showing improved progression-free survival with camizestrant.